Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427539 | 1.00 | FAAH (0.53) | FAAHMTNR1AMTNR1BANPEPPLAU | |
| SCHEMBL5608206 | 1.00 | FAAH (0.53) | FAAHMTNR1AMTNR1BANPEPPLAU | |
| Hydrochloric Acid SCHEMBL9266537 | 0.98 | ANPEP (0.53) | FAAHMTNR1AMTNR1BANPEPPLAU | |
| SCHEMBL3519807 | 0.90 | RAB9A (0.48) | FAAHMTNR1AMTNR1BANPEPPLAU | |
| SCHEMBL3525109 | 0.89 | MME (0.45) | FAAHMTNR1AMTNR1BANPEP | |
| SCHEMBL289302 | 0.85 | AKR1C3 (0.50) | FAAHP2RX7AKR1C3AKR1C1 | |
| SCHEMBL29443025 | 0.85 | AKR1C3 (0.50) | FAAHP2RX7AKR1C3AKR1C1 | |
| SCHEMBL1193346 | 0.84 | FAAH (0.53) | FAAHMTNR1AMTNR1BANPEPPLAU | |
| SCHEMBL6534185 | 0.84 | FAAH (0.53) | FAAHMTNR1AMTNR1BANPEPPLAU | |
| SCHEMBL7352959 | 0.83 | AKR1C3 (0.48) | FAAHAKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 582 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939748-B | Method for preparing deuterated compound through decarboxylation and deuteration of carboxylic acid | 中国科学院大连化学物理研究所 | 2022-11-01 | — | — | CN | claimed |
| CN-112939748-A | Method for preparing deuterated compound through decarboxylation and deuteration of carboxylic acid | 中国科学院大连化学物理研究所 | 2021-06-11 | — | — | CN | claimed |
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | claimed |
| CN-104419326-A | Slurry composition for chemical mechanical polishing | COWON INNOTECH INC | 2015-03-18 | — | — | CN | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050209297-A1 | Pyrazole derivatives | PFIZER INC | 2005-09-22 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-5652093-A | Analogues of reporter groups as background reducers in binding assays | APROGENEX, INC. (US) | 1997-07-29 | — | — | US | claimed |
| US-5501952-A | Analogues of reporter groups as background reducers in hybridization assays | APROGENEX, INC. (US) | 1996-03-26 | — | — | US | claimed |
| WO-1995002699-A1 | ANALOGUES OF REPORTER GROUPS AS BACKGROUNG REDUCERS IN HYBRIDIZATION ASSAYS | APROGENEX, INC. (US) | 1995-01-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209297-A1 | Pyrazole derivatives | CDK1, CDK3, CDK5 | FAAH 4593/4885MTNR1A 1188/4885MTNR1B 1920/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | FAAH 4822/4885MTNR1A 830/4885MTNR1B 1118/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | FAAH 1258/4885MTNR1A 3547/4885MTNR1B 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.